Artificial Intelligence for Biotechnology and Digital Health

We support biotech, pharma and medtech companies moving forward with artificial intelligence technology.

Clients

Experts

Managing Director (CEO)
paul.buenau@idalab.de
+49 173 24 16 000

Dr. Paul von Bünau

Services

Artificial intelligence creates new opportunities and threats. Define a clear strategy first to then focus on the right use cases.
Building custom AI technology can create a true advantage, but needs a more sophisticated approach than “software with a PoC”.
“Value from data and AI” can be tremendous, but finding tangible opportunities is harder than high-level narratives suggest.
Many workflows in market access and pricing are well suited to acceleration by AI. But big impact rarely comes from plugging in off-the-shelf tools.

Senior Associate
julian.beimes@idalab.de
+49 173 6762781

Julian Beimes

Services

Make regulatory strategy a part of your proof-of-concept, because there is no product without compliance. Don’t leave this to the lawyers.
A medical device footprint is an excellent starting point for AI, with its own hurdles: legacy systems, regulation and established care models.

Client stories

How a drug discovery startup used AI to read 10,000 papers and zero in on their ideal targets

How Matchpoint Therapeutics accelerated discovery by fusing siloed data into a unified pipeline

What our clients say

“idalab have worked seamlessly with our research leaders to implement a target discovery engine that captures our unique insight but can be scaled across biological classes. Pragmatic and cutting-edge. Great team!”
Jonathan Montagu
CEO
HotSpot Therapeutics
“It is a pleasure working with the idalab team on our data and machine learning pipeline. They are an outstanding strategic partner, collaborating seamlessly with our science team. Fast, clear communication, structured – yet always happy to adapt ad hoc, if necessary. We are looking forward to continuing the collaboration.”
Suresh Singh, PhD
SVP Computational Science
Matchpoint Therapeutics
”Working with the idalab team was truly amazing and inspiring. Experienced as they are, they demonstrated all but telepathic abilities, immediately understanding our project’s requirements. Integrating data/AI and biology know-how, idalab helped us find innovative solutions to hard challenges: a true (and fun!) creative partnership. Highly recommended!”
Dr. Markus Rinecker
CMO/CFO
mbiomics

Insights

Insights

Generative AI at the Gate: Impressions from the World EPA Congress 2025

Was this year’s EPA the last of the pre-AI era? Judging by the number of newly AI-enabled service providers at EPA 2025, a tectonic shift is under way in the industry. This shift was reflected in two (out of four!) keynotes on AI, and a highly popular track on digital transformation. Why is that and what lies ahead?

No-nonsense: How ChatGPT-Technology helps Biotechs find better Drug Targets faster

Large Language Models are poised to become an indispensable tool for biotechs looking to find their ideal drug targets. Evidence-grounded LLMs can sift through millions of publications, finding highly specific pieces of evidence in seconds, unlocking overlooked drug target opportunities.

Into the unknown: biotech’s quest to target the 'undruggable' proteome

Novel therapeutic modalities, such as PROTACs, allow access to formerly undruggable parts of the proteome, shifting the frontiers of drug discovery. Artificial intelligence-based target scoring algorithms can help biotechs prioritize disease-relevant proteins as modality tailored drug targets.

Featured (more)

Events

Upcoming

Events